Business / Corporate Mar 29, 2019
AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatment
Britain’s AstraZeneca’s biggest deal in recent memory give it access to the Japanese drugmaker’s promising but difficult to pronounce cancer treatment: trastuzumab deruxtecan.
